Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years
- PMID: 22529255
- DOI: 10.1200/JCO.2011.40.1836
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years
Abstract
Purpose: Preoperative chemoradiotherapy (CRT) has been established as standard treatment for locally advanced rectal cancer after first results of the CAO/ARO/AIO-94 [Working Group of Surgical Oncology/Working Group of Radiation Oncology/Working Group of Medical Oncology of the Germany Cancer Society] trial, published in 2004, showed an improved local control rate. However, after a median follow-up of 46 months, no survival benefit could be shown. Here, we report long-term results with a median follow-up of 134 months.
Patients and methods: A total of 823 patients with stage II to III rectal cancer were randomly assigned to preoperative CRT with fluorouracil (FU), total mesorectal excision surgery, and adjuvant FU chemotherapy, or the same schedule of CRT used postoperatively. The study was designed to have 80% power to detect a difference of 10% in 5-year overall survival as the primary end point. Secondary end points included the cumulative incidence of local and distant relapses and disease-free survival.
Results: Of 799 eligible patients, 404 were randomly assigned to preoperative and 395 to postoperative CRT. According to intention-to-treat analysis, overall survival at 10 years was 59.6% in the preoperative arm and 59.9% in the postoperative arm (P = .85). The 10-year cumulative incidence of local relapse was 7.1% and 10.1% in the pre- and postoperative arms, respectively (P = .048). No significant differences were detected for 10-year cumulative incidence of distant metastases (29.8% and 29.6%; P = .9) and disease-free survival.
Conclusion: There is a persisting significant improvement of pre- versus postoperative CRT on local control; however, there was no effect on overall survival. Integrating more effective systemic treatment into the multimodal therapy has been adopted in the CAO/ARO/AIO-04 trial to possibly reduce distant metastases and improve survival.
Comment in
-
Long-term follow-up of a paradigm-changing study: the paradigm still holds.J Clin Oncol. 2012 Jun 1;30(16):1901-3. doi: 10.1200/JCO.2012.41.8863. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529256 No abstract available.
Similar articles
-
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15. Lancet Oncol. 2015. PMID: 26189067 Clinical Trial.
-
Persistent Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Rectal Cancer.JAMA Netw Open. 2024 Sep 3;7(9):e2432927. doi: 10.1001/jamanetworkopen.2024.32927. JAMA Netw Open. 2024. PMID: 39264626 Free PMC article.
-
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.Ann Oncol. 2018 Aug 1;29(8):1793-1799. doi: 10.1093/annonc/mdy205. Ann Oncol. 2018. PMID: 29873684 Clinical Trial.
-
Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?Strahlenther Onkol. 2010 Dec;186(12):658-64. doi: 10.1007/s00066-010-2194-2. Epub 2010 Nov 30. Strahlenther Onkol. 2010. PMID: 21136027 Review.
-
Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer.Cochrane Database Syst Rev. 2012 Dec 12;12:CD008368. doi: 10.1002/14651858.CD008368.pub2. Cochrane Database Syst Rev. 2012. PMID: 23235660 Review.
Cited by
-
The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative Management.Oncol Hematol Rev. 2020 Spring;16(1):43-51. Epub 2020 Apr 27. Oncol Hematol Rev. 2020. PMID: 32832093 Free PMC article.
-
The effect of Inc parameter on VMAT radiotherapy plans quality for rectal cancer using Monaco TPS.J Appl Clin Med Phys. 2024 Sep;25(9):e14409. doi: 10.1002/acm2.14409. Epub 2024 Jun 24. J Appl Clin Med Phys. 2024. PMID: 38923699 Free PMC article.
-
[Role of neoadjuvant radiotherapy for rectal cancer : Is MRI-based selection a future model?].Chirurg. 2016 Jul;87(7):573-8. doi: 10.1007/s00104-016-0236-8. Chirurg. 2016. PMID: 27339645 German.
-
GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.Oncotarget. 2016 Oct 18;7(42):68328-68338. doi: 10.18632/oncotarget.12008. Oncotarget. 2016. PMID: 27634904 Free PMC article.
-
Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients.World J Surg. 2015 May;39(5):1257-67. doi: 10.1007/s00268-014-2917-0. World J Surg. 2015. PMID: 25561186
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials